https://www.onclive.com/view/fda-grants-fast-track-designation-to-emactuzumab-for-unresectable-tgct
FDA Grants Fast Track Designation to Emactuzumab for Unresectable TGCT | OncLive
Oct 5, 2026 - The FDA granted fast track designation to emactuzumab for unresectable tenosynovial giant cell tumor.
fast track designationfdagrantsemactuzumabunresectable